Feb. 2 at 2:39 PM
$PACB PacBio () announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina. PacBio received
$48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual property back to PacBio. The transaction closed on January 30, 2026.